How we rate what works
What we rate
A use case is one kind of work done with AI, such as answering customer queries or writing code. For each one we ask: when people use AI for it, what happens to their time, output and quality? We answer only from published studies, never from our own impressions, vendor claims or surveys of opinion.
Each rating has four parts, shown side by side and never combined into one score: a verdict (which way the evidence points), the impact (how big the effect is, outcome by outcome), the strength of the evidence (how sure we can be, 0 to 5) and the cost.
What counts as a study
A study enters our evidence map when it measures what happened when people used generative AI (a model released from November 2022) for real or realistic work; it reports an outcome such as time, output, quality, errors, cost, wellbeing or learning; it compares against people without AI, or before and after; and it is public, as a journal article, working paper or published evaluation.
Vendor case studies and press releases can enter only at the lowest grade and never decide a verdict alone.
In practice, “a model released from November 2022” means the study's fieldwork ran mainly after that date with a generative AI tool. Studies whose tool and fieldwork came earlier, or that test a different use, are listed on each page as context but not counted.
How studies are graded
| Grade | What it means |
|---|---|
| A | A well-run randomised trial in real, deployed work: pre-registered, few drop-outs, outcomes measured rather than self-reported. |
| B | A strong natural experiment in real work (for example a staggered rollout), or a well-run randomised trial on realistic tasks. |
| C | A trial or natural experiment with clear limits (small, short, many drop-outs), or a well-matched comparison of users and non-users. |
| D | Before-and-after without a comparison group, surveys, self-report-only trials and vendor case studies. |
How sure are we? Evidence strength from 0 to 5
| Level | Needs | What we say |
|---|---|---|
| 5 | 6 or more grade A studies | We have very high confidence in this estimate. |
| 4 | 4 or 5 grade A or B studies | We have high confidence in this estimate. |
| 3 | 2 or 3 grade A or B studies, or 6 or more grade C | We have moderate confidence in this estimate. |
| 2 | 2 or more studies graded A, B or C | We have low confidence in this estimate. |
| 1 | Any 2 or more studies, including grade D | We have very low confidence in this estimate. |
| 0 | Fewer than 2 qualifying studies | There is not enough evidence to rate this yet. No impact figure is shown. |
Then the level drops by one for each problem: inconsistent results that nothing explains (never with only two studies); old models, when fewer than half the studies used a model released in the last 18 months (today: since May 2025); not independent, when most studies were run, funded or written by the company whose AI was tested, or the effect shrinks without them; not real work, when most studies used lab or benchmark tasks; self-reported, when the headline outcome is what people said rather than what was measured; and publication bias, tested once 10 or more studies allow it.
Evidence made only of grade D studies cannot start above 1; only C and D, not above 3; with no grade A, not above 4. Working papers and preprints are flagged but not deducted, because much of the best evidence on AI at work is not yet in journals.
How impact is shown
One row per outcome (time, output, quality, errors, learning and so on), never one fused score. Each row shows the studies' own numbers and a plain band:
| Band | Time or output | Quality or scores |
|---|---|---|
| Worse | Takes longer, or output falls | Quality falls or errors rise |
| No clear effect | Under 5%, or not statistically clear | Not statistically clear |
| Small gain | 5–15% | Up to 0.2 standard deviations |
| Moderate gain | 15–30% | 0.2–0.5 standard deviations |
| Large gain | Over 30% | Over 0.5 standard deviations |
Each study adds one result to the headline outcome. Where a study tests two products or several tasks against one control, we count its least favourable result and show the others alongside.
These bands are provisional until the map holds 30 pooled effects; then they will come from the map's own spread of results. Where a study counts the time people spend checking the AI's output, the time figure includes it; where it does not, the page says so.
How the verdict is decided
| Verdict | Rule |
|---|---|
| Works | A gain, statistically clear, strength 3 or more, no unexplained differences between studies. Said as “works” (4–5) or “probably works” (3). |
| Works for some | A gain on average, with differences explained by a factor we named in advance, such as experience or task type. We always say who: “may work for less experienced agents”. |
| Mixed | Some studies show gains and some losses, with no clear overall effect; strength 2 or more. |
| Not enough evidence yet | Strength 0 or 1, whatever the direction. At strength 2 or more, a gain with no named factor is shown as “may help”, and a result with no clear effect either way as “no clear effect so far”. |
| Evidence against | The effect is in the worse band, or there is no net gain once checking time is counted; strength 2 or more. |
The verb carries the certainty: “works”, “probably works”, “may work”. We never say “proven”. A verdict is computed by these rules, not chosen; if we ever think the rules give the wrong answer, we publish the exception and the reason.
Cost
| Band | Per user per year (US dollars) |
|---|---|
| $ | Under $100 |
| $$ | $100–$499 |
| $$$ | $500–$1,499 |
| $$$$ | $1,500 or more |
| ? | Uncertain or varies too much |
We count licences, setup, training and the time people spend checking the output, and leave out what an organisation already has. Bands are reviewed every year.
How, where and why it works
Every use case also gets four scores from 0 to 4, never added up: do the studies tell us why it works, for whom, what it takes (training, review steps, data) and what it really costs? This is the EMMIE method used by the UK College of Policing's What Works Centre.
What is still a pilot
These are pilot ratings. Three simplifications apply until the evidence map is bigger, and each page says so:
No pooling yet. Each impact row shows the range across studies and is banded on their median, instead of a pooled estimate with an interval. Equal weights. Each study counts once, whatever its size. Model age by date. The old-models test uses release dates only.
The rules are written down and dated here before any rating changes. We still plan to register them publicly (on the Open Science Framework), recruit an independent methods reviewer, and appoint named reviewers for health, legal and finance pages. Until a domain reviewer signs a health, legal or finance page off, that page is kept out of search engines.
Trials to watch
| Trial | Use | Registry |
|---|---|---|
| Generative AI training for relationship managers at a large bank (BBVA) Cluster trial across bank branches with conversion and sales outcomes: the first sales study. | Sales | AEA RCT Registry AEARCTR-0019338 |
| Generative AI and productivity in the Global South (loan officers at a Ugandan bank) Pair-matched cluster trial of a decision-support tool for loan officers. | Finance and insurance | AEA RCT Registry AEARCTR-0018778 |
| AI help for certified financial planners (Canada) Planners randomised to advise with or without a generative AI tool. | Finance and insurance | AEA RCT Registry AEARCTR-0018280 |
| Productivity impact of generative AI in the public sector (Australian public servants) Policy tasks done with and without AI, graded independently. | Public service | AEA RCT Registry AEARCTR-0014140 |
| Research writing with generative AI (Peking University) Registered trial of AI help with research writing; registry page not yet read. | Research | AEA RCT Registry AEARCTR-0017030 |
| AI and acquisition decisions by senior MedTech and biotech managers 400 senior managers randomised to web search, ChatGPT or an agent system on an acquisition case. Ends December 2026. | Management | AEA RCT Registry AEARCTR-0016459 |
| Phone calls from an AI voice agent at a German technology company 8,000 customers phoned by an AI agent to book appointments, with or without a reason given for using AI. Tests how it is framed, not AI against people. Listed end date has passed; no results posted. | Sales | AEA RCT Registry AEARCTR-0017259 |
| AI coaching, performance and wellbeing among office employees 38,000 employees in 96 countries, staggered access to an AI coaching chatbot, with administrative performance data. Runs to December 2028. | Wellbeing | Nuffield Foundation project page (no registry entry found) |
Registered trials whose results are not public yet, checked in our monthly search (last checked 5 Nov 2026). When results appear, each is read and checked like any other study; some will give sectors such as finance their first rated use cases.
Who checks what
AI research agents search for studies and read each paper. A second, separate pass re-opens every paper and checks every number we show against it, recording the quote and where it appears. Ratings are then computed by code from the graded studies. Nothing is rated from memory, from news reports or from a company's own summary of a study.
Disclosure: AI Adoption uses AI tools, including Claude from Anthropic, in its research and editorial work. No company pays for or has any say in a rating. Spot a mistake? Corrections.
Change log
| Date | Change |
|---|---|
| 5 Nov 2026 | Forty more study records graded from a search of the most-used work activities, each checked a second time (batches 12 to 14; four more were left out as off topic). Six new use cases: finding information, summarising, notes and records, explaining rules, requirements and design, and slides. One rating changed: data analysis moved from “no clear effect so far” to “mixed results”, strength unchanged at 2, because a pre-registered trial at the Central Bank of Ireland found lower accuracy with AI. Three trials added to Trials to watch. The map now holds 145 studies (114 counted). See Most used vs best studied. |
| 2 Nov 2026 | Rules v0.3, approved by the owner: the model-date rule read as fieldwork mainly after November 2022; “not real work” triggered by lab or benchmark tasks only; one headline result per study, the least favourable; “no clear effect so far” for no clear effect at strength 2 or more. These were already applied to the first ratings, so no rating changed. |
| 2 Nov 2026 | Four jobs added: hiring and recruitment, creative and design work, scientific research and translation, with six new use cases (batches 10 and 11, each checked a second time). The map now holds 145 studies (114 counted). Earlier ratings did not change; one creative-writing study moved from context into the new creative use case. Five registered trials are listed under Trials to watch. |
| 2 Nov 2026 | Professional services and software and tech added: five new use cases (data analysis, AI in code review, AI in IT and security support, AI in financial analysis, AI-written marketing content) and two sector pages. Finance and retail have too little rated evidence for sector pages yet. The map held 82 studies (72 counted). Earlier ratings did not change. |
| 2 Nov 2026 | Health care and education added: five new use cases (AI drafts of patient replies, AI help with diagnosis, lesson planning, AI feedback on student work, AI support for tutors) and two sector pages. The map held 62 studies (54 counted). Ratings of the first nine use cases did not change. |
| 2 Nov 2026 | First pilot ratings published: 9 use cases, 41 studies (32 counted). |